MGC Pharmaceuticals has officially completed its transition to a new corporate identity, rebranding as Argent BioPharma following shareholder approval of the change last month.
The Australian Securities and Investments Commission (ASIC) has processed the name change, which took effect on the ASX at the open of trading on Wednesday, April 3.
The company's ASX ticker has moved to RGT, and its new web address is www.argentbiopharma.com.
Existing shareholdings remain unchanged and no new share certificates will be issued to investors.
Argent BioPharma Managing Director and CEO Roby Zomer said: "As Argent BioPharma emerges from MGC Pharma, it is well positioned in the new era in biopharmaceuticals, committed to providing accessible and impactful healthcare solutions on a global scale.
"This rebranding signifies our commitment to innovation and advancement in the biopharmaceutical landscape.
"We are excited to leverage our expertise in polypharmacology and nanotechnology to pioneer ground-breaking treatments, addressing unmet medical needs and driving positive change in global healthcare."
